JHS SVENDGAARD LABORATORIES LTD.

JHS Svendgaard Laboratories Ltd has announced the closure of its trading window for the quarter ended June 30, 2026. This measure, in compliance with SEBI regulations and the company's insider trading code, restricts dealings in the company's securities by insiders and designated persons. The window will reopen 48 hours after the declaration of the unaudited financial results for the said quarter. The specific date of the board meeting to consider these results will be communicated later.

JHS Svendgaard Laboratories Ltd has filed a statement of deviation for the quarter ended March 31, 2026, regarding the utilization of funds raised through a preferential issue. The Board of Directors approved this statement on May 26, 2026. According to the filing, there was no deviation or variation in the use of funds raised. The funds were raised on June 4, 2024, amounting to ₹29.99 crores.

JHS Svendgaard Laboratories Ltd announced audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results in a meeting held on May 26, 2026, after review and recommendation by the Audit Committee. The auditor, V.K. Khosla & Co., issued an unmodified opinion on the standalone and consolidated financial results. The board meeting commenced at 3:40 P.M. and concluded at 4:30 P.M. Details are available on the company website.

JHS Svendgaard Laboratories Ltd's Board of Directors approved the audited financial results for the quarter and financial year ended March 31, 2026, during its meeting held on May 26, 2026. The results, reviewed and recommended by the Audit Committee, include standalone and consolidated financials. Auditor's Report with unmodified opinion was issued by V.K. Khosla & Co., Chartered Accountants. The board meeting commenced at 3:40 P.M. and concluded at 4:30 P.M. The information is available on the company's website.

JHS Svendgaard Laboratories Ltd has scheduled a Board of Directors meeting on May 26, 2026, to consider and approve the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026. The trading window has been closed from April 1, 2026, and will remain closed until 48 hours after the announcement of the results.

JHS Svendgaard Laboratories Ltd has completed the change of its Registrar and Share Transfer Agent (RTA). The company entered into a tripartite agreement on April 27, 2026, with Alankit Assignments Limited (old RTA) and Beetal Financial & Computer Services (P) Limited (new RTA). This change is effective from April 27, 2026, and aims to strengthen the company's investor services function. All formalities for the transition have been completed.

JHS Svendgaard Laboratories Ltd has confirmed the change of its Registrar and Share Transfer Agent (RTA) from Alankit Assignments Limited to Beetal Financial and Computer Services (P) Ltd. This change follows an earlier intimation and is in compliance with SEBI regulations. The company's primary reason for this transition is to enhance and strengthen its investor services function. A tripartite agreement involving the company, the outgoing RTA (Alankit Assignments Limited), and the new RTA (Beetal Financial and Computer Services Private Ltd) is currently being processed. The effective date for this change will be communicated to the stock exchanges once all definitive agreements are finalized.

JHS Svendgaard Laboratories Ltd has announced the closure of the trading window for all insiders, including designated persons and their relatives. The closure will be in effect from Wednesday, April 1, 2026, until 48 hours after the declaration of the audited financial results for the quarter and year ended March 31, 2026. The date of the board meeting where the results will be considered will be intimated in due course. This announcement is in accordance with the SEBI (Prohibition and Insider Trading) Regulations, 2015 and the company’s ‘Code of Conduct for Prevention of Insider Trading’.

JHS Svendgaard Laboratories Ltd. has reported no deviation in the utilization of funds raised through a preferential issue, as per the Statement of Deviation or Variation for the quarter ended December 31, 2025. The company raised Rs. 29.99 crores on June 4, 2024, for setting up a new project in Jammu & Kashmir and for general corporate purposes. The company also infused funds into its group entity, JHS Svendgaard Retail Ventures Ltd., for funding the expansion plan. All these allocations and utilizations are as per the approved objects.

JHS Svendgaard Laboratories Ltd. has approved the un-audited standalone and consolidated financial results for the quarter and nine months ended 31st December, 2025. The board meeting was held on 10th February, 2026 and the results were prepared in accordance with the Indian Accounting Standards (Ind AS) and other accounting principles generally accepted in India. The company has utilized the funds received for project in Jammu and Kashmir, general corporate purpose, investment in preferential warrants, capital expenditure, and fixed deposits.